Commure vs DeepScribe (2026)
Both sell documentation with coding attached; the resemblance stops there. Commure, the General Catalyst backed roll up of Athelas, Augmedix, and Memora, treats the note as the front end of claims automation and sells oversight as a spectrum: Go for AI drafted notes, Assist adding specialist review, and Live with synchronous human documentation, across a claimed 50 plus EHRs and a reported 250,000 plus providers. DeepScribe treats the note as a specialty craft: oncology as its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, HCC, CPT, and ICD-10 suggestions built into the note, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight. If your failure mode is clinicians or specialties that still need a human in the documentation loop, or notes that must feed claims automation, start with Commure. If your failure mode is complex specialty documentation that generalist scribes get wrong, start with DeepScribe. Neither publishes pricing.
- Oversight is a dial: Go delivers AI drafted notes, Assist adds specialist review, and Live provides synchronous human documentation, the only purchasable human review in this pairing.
- Estate and procurement reach: more than 50 EHRs including Epic, Oracle Health, and MEDITECH across ambulatory and acute settings, a reported 250,000 plus providers, and a January 2025 Vizient contract giving member health systems a negotiated path.
- Documentation feeds revenue cycle: ambient output flows into autonomous coding, clinical documentation integrity, and claims automation, backed by a public trust center, a published standard Business Associate Agreement, and stated data export in FHIR, CSV, and JSON.
- Specialty depth is the requirement: oncology first with a reported 5 million oncology visits a year and roughly 40 percent of US cancer care visits documented, plus tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology.
- The independent signal is one sided: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six categories, 2025 KLAS Top 5 rankings, and an August 2025 Journal of Clinical Pathways study in oncology, where Commure's clinical evidence is unassessed on this index.
- Coding lives in the note: bidirectional integration reads the chart before the visit and writes structured data into discrete EHR fields after, with HCC, CPT, and ICD-10 suggestions built into the note, in more than 110 languages.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Commure and DeepScribe are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Commure | DeepScribe |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2017 | 2017 |
| Headquarters | Mountain View, California | San Francisco, California |
| Website | commure.com | deepscribe.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Commure its top capability grade on AI Centrality. Set against DeepScribe, Commure grades higher on AI Safety and PHI Stewardship and Security Certifications and Trust Center. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards DeepScribe its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and EHR and Interoperability Depth. Set against Commure, DeepScribe grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Commure or DeepScribe?
On the axes where the AI Health Index separates them, Commure grades higher on AI Safety and PHI Stewardship and Security Certifications and Trust Center, and DeepScribe grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and AI Liability and Recourse. DeepScribe leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Commure and DeepScribe differ most?
The widest separation the AI Health Index records between Commure and DeepScribe is on Clinical and Operational Evidence, where Commure grades C and DeepScribe grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Commure and DeepScribe grade the same?
The AI Health Index grades Commure and DeepScribe the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Commure and DeepScribe not disclosed?
At the last review, at least one of Commure and DeepScribe published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Provider and visit figures for both vendors are vendor published, including Commure's 250,000 plus providers and DeepScribe's oncology share. DeepScribe's KLAS scores are buyer survey based, and the Emerging Company Spotlight is a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane; Commure's clinical evidence is unassessed on this index.
Two Commure trust center caveats are recorded: the independent audit claim is ambiguously worded with no named certification or date, with the SOC 2 Type 2 reference attaching to its data centers rather than to Commure itself, and the purpose limitation language does not state whether PHI is used to train models. Neither vendor publishes pricing. Third party estimates place DeepScribe at $350 to $500 per provider per month with some reports near $750; no third party figure is recorded for Commure. All estimates are unconfirmed.